Bandel L. Carano - Aug 3, 2022 Form 4 Insider Report for NEOPHOTONICS CORP (NPTN)

Role
Director
Signature
/s/ John Sellers, Attorney-in-fact
Stock symbol
NPTN
Transactions as of
Aug 3, 2022
Transactions value $
$0
Form type
4
Date filed
8/5/2022, 04:57 PM
Previous filing
Jun 23, 2022
Next filing
Dec 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NPTN Common Stock Disposed to Issuer -29K -100% 0 Aug 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NPTN Non-Qualified Stock Option (right to buy) Disposed to Issuer -14.1K -100% 0 Aug 3, 2022 Common Stock 14.1K $4.33 Direct F2
transaction NPTN Non-Qualified Stock Option (right to buy) Disposed to Issuer -8.96K -100% 0 Aug 3, 2022 Common Stock 8.96K $8.56 Direct F2
transaction NPTN Non-Qualified Stock Option (right to buy) Disposed to Issuer -7.64K -100% 0 Aug 3, 2022 Common Stock 7.64K $10.17 Direct F2
transaction NPTN Restricted Stock Unit (right to acquire) Disposed to Issuer -5.79K -100% 0 Aug 3, 2022 Common Stock 5.79K $0.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Bandel L. Carano is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated November 3, 2021, by and among the Issuer, Lumentum Holdings Inc., a Delaware corporation ("Lumentum"), and Neptune Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Lumentum ("Merger Sub"), on August 3, 2022 (the "Closing Date"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Lumentum. In connection with the Merger, these shares were cancelled and converted into the right to receive $16.00 in cash, without interest, per share, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F2 Options to purchase common stock of the Issuer, whether vested or unvested as of immediately prior to the Closing Date, were cancelled and converted into the right to receive the Merger Consideration, less the exercise price per share of such cancelled option.
F3 Restricted Stock Unit Awards of the Issuer, whether vested or unvested as of immediately prior to the Closing Date, were cancelled and converted into the right to receive the Merger Consideration.

Remarks:

Exhibit List Exhibit 24: Authorization Letter